625 related articles for article (PubMed ID: 26579854)
1. Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial.
Tzanetakou V; Kanni T; Giatrakou S; Katoulis A; Papadavid E; Netea MG; Dinarello CA; van der Meer JWM; Rigopoulos D; Giamarellos-Bourboulis EJ
JAMA Dermatol; 2016 Jan; 152(1):52-59. PubMed ID: 26579854
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Glatt S; Jemec GBE; Forman S; Sayed C; Schmieder G; Weisman J; Rolleri R; Seegobin S; Baeten D; Ionescu L; Zouboulis CC; Shaw S
JAMA Dermatol; 2021 Nov; 157(11):1279-1288. PubMed ID: 34406364
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
Bechara FG; Podda M; Prens EP; Horváth B; Giamarellos-Bourboulis EJ; Alavi A; Szepietowski JC; Kirby J; Geng Z; Jean C; Jemec GBE; Zouboulis CC
JAMA Surg; 2021 Nov; 156(11):1001-1009. PubMed ID: 34406349
[TBL] [Abstract][Full Text] [Related]
5. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
8. A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa.
Miller I; Lynggaard CD; Lophaven S; Zachariae C; Dufour DN; Jemec GB
Br J Dermatol; 2011 Aug; 165(2):391-8. PubMed ID: 21457202
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
10. Failure of Anakinra in a Case of Severe Hidradenitis Suppurativa.
Russo V; Alikhan A
J Drugs Dermatol; 2016 Jun; 15(6):772-4. PubMed ID: 27272089
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
13. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB; Jemec GBE; Alavi A; Reguiai Z; Gottlieb AB; Bechara FG; Paul C; Giamarellos Bourboulis EJ; Villani AP; Schwinn A; Ruëff F; Pillay Ramaya L; Reich A; Lobo I; Sinclair R; Passeron T; Martorell A; Mendes-Bastos P; Kokolakis G; Becherel PA; Wozniak MB; Martinez AL; Wei X; Uhlmann L; Passera A; Keefe D; Martin R; Field C; Chen L; Vandemeulebroecke M; Ravichandran S; Muscianisi E
Lancet; 2023 Mar; 401(10378):747-761. PubMed ID: 36746171
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Hidradenitis Suppurativa Investigator Global Assessment: A Novel Hidradenitis Suppurativa-Specific Investigator Global Assessment for Use in Interventional Trials.
Garg A; Zema C; Ciaravino V; Rolleri R; Peterson L; Garcia L; Massaro T; Jemec GBE; Kirby JS; Thorlacius L; Ingram JR
JAMA Dermatol; 2023 Jun; 159(6):606-612. PubMed ID: 37099284
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hidradenitis suppurativa with etanercept injection.
Adams DR; Yankura JA; Fogelberg AC; Anderson BE
Arch Dermatol; 2010 May; 146(5):501-4. PubMed ID: 20479297
[TBL] [Abstract][Full Text] [Related]
17. Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial.
Vossen ARJV; van Doorn MBA; van der Zee HH; Prens EP
J Am Acad Dermatol; 2019 Jan; 80(1):80-88. PubMed ID: 30482392
[TBL] [Abstract][Full Text] [Related]
18. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M
Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429
[TBL] [Abstract][Full Text] [Related]
19. Use of biological treatments in patients with hidradenitis suppurativa.
Martin-Ezquerra G; Masferrer E; Pujol RM
G Ital Dermatol Venereol; 2017 Aug; 152(4):373-378. PubMed ID: 27982551
[TBL] [Abstract][Full Text] [Related]
20. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies.
Alavi A; Hamzavi I; Brown K; Santos LL; Zhu Z; Liu H; Howell MD; Kirby JS
Br J Dermatol; 2022 May; 186(5):803-813. PubMed ID: 34978076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
